What drug class does hyoscyamine belong to?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Hyoscyamine Drug Class

Hyoscyamine is an anticholinergic/antispasmodic agent, specifically a competitive antagonist of acetylcholine at muscarinic receptors. 1

Primary Classification

Hyoscyamine belongs to the anticholinergic/antimuscarinic class of medications. It is one of the principal anticholinergic/antispasmodic components of belladonna alkaloids 1. More specifically, it functions as a competitive antagonist of acetylcholine muscarinic (M-) receptors that potently modulates both the central and peripheral nervous systems 2.

Mechanism and Pharmacologic Properties

The drug works by:

  • Blocking muscarinic acetylcholine receptors, thereby inhibiting parasympathetic nervous system activity
  • Reducing smooth muscle contraction in the gastrointestinal tract 3
  • Decreasing visceral hypersensitivity 3

Clinical Context

Within the broader therapeutic framework, hyoscyamine is classified as an antispasmodic when used for gastrointestinal conditions 3, 4. The AGA guidelines specifically categorize it among antispasmodics available in the United States (along with hyoscine, dicyclomine, and peppermint oil) for treating irritable bowel syndrome 3.

The drug is chemically a tropane alkaloid 2, 5, derived from belladonna alkaloids, with the empirical formula (C17H23NO3)2 • H2SO4 • 2H2O 1.

Important Clinical Caveat

While hyoscyamine is pharmacologically diverse as part of the antispasmodic class, its anticholinergic effects may limit regular use in patients with constipation 3. Common anticholinergic adverse effects include dry mouth, dizziness, and blurred vision 3, and notably, sinus tachycardia has been observed in up to 27% of patients receiving intravenous formulations 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.